Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | -$4.42M | -$4.95M | -$12.3M | -$14.9M | -$9.94M | -$4.50M |
| Net income | -$4.41M | -$5.05M | -$12.4M | -$14.9M | -$9.95M | -$4.51M |
| EPS (diluted) | -$0.06 | -$0.07 | -$0.14 | -$22.89 | -$132.33 | -$11.32 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$2.35M | -$2.71M | -$6.61M | -$8.92M | -$8.27M | -$6.57M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $90.3K | $1.93M | $14.1M | $5.14M | $376K | $3.95M |
| Total assets | $1.81M | $2.91M | $14.5M | $5.92M | $632K | $4.60M |
| Total liabilities | — | $900K | $1.16M | $2.87M | $3.23M | $635K |
| Shareholders' equity | $822K | $2.01M | $13.4M | $3.05M | -$2.59M | $3.97M |
| Retained earnings | -$11.8M | -$16.8M | -$29.2M | -$44.1M | -$54.0M | -$58.5M |
| Shares (wtd avg diluted) | 64.8M | 72.7M | 89.1M | 650K | 74.2B | 451K |
Every figure is extracted from Alzamend Neuro, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.